Eloïne Bestion

3PUBLICATIONS
9CO-AUTHORS
Molecular targetsCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

Sort by Publication Date:
|Aug 15, 2024
Autophagy in cancer resistance: New combinatorial strategy for cancer therapy.

Eloïne Bestion, Régis Costello, Soraya Mezouar

|Jul 14, 2023
Update on Autophagy Inhibitors in Cancer: Opening up to a Therapeutic Combination with Immune Checkpoint Inhibitors.

Eloïne Bestion, Eric Raymond, Soraya Mezouar

|Nov 06, 2021
GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions.

Sonia Brun, Eloïne Bestion, Eric Raymond

Pageof 1

Frequent Collaborators

1 joint publications

Sonia Brun

1 joint publications

Eric Raymond

1 joint publications

Zuzana Macek Jilkova

1 joint publications

Soraya Mezouar

1 joint publications

Marie Novello

1 joint publications

Gilles Lalmanach

1 joint publications

Gael Roth

1 joint publications

Jean-Pierre Baudoin

1 joint publications

Thomas Decaens

Frequent Collaborators

1 joint publications

Sonia Brun

1 joint publications

Eric Raymond

1 joint publications

Zuzana Macek Jilkova

1 joint publications

Soraya Mezouar

JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us

Top Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on : Dec 11, 2017

7.2K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on : Mar 07, 2025

446
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on : Jul 12, 2018

8.8K
See more related videos

Top Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on : Dec 11, 2017

7.2K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on : Mar 07, 2025

446
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on : Jul 12, 2018

8.8K
See more related videos